CLCM
VKTX icon

Crawford Lake Capital Management’s Viking Therapeutics VKTX Stock Holding History

Crawford Lake Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-110,019
Closed -$1.92M – 77
2018
Q3 		$1.92M Buy
+110,019
New +$1.31M 0.37% 48

Other funds holding VKTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Crawford Lake Capital Management's VKTX Position: Q4 2018 in Review

Crawford Lake Capital Management sold out of Viking Therapeutics (VKTX) in Q4 2018, closing a stake of 110,019 shares — an estimated $1.92M sold.

Crawford Lake Capital Management first reported a position in VKTX in Q3 2018 and held it in 1 quarter. The position peaked at $1.92M in Q3 2018. 168 funds tracked by Wall St. Rank hold VKTX as of Q4 2018.

  • Crawford Lake Capital Management reported no remaining Viking Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Crawford Lake Capital Management sold 110,019 Viking Therapeutics shares in Q4 2018, an estimated $1.92M.
  • Crawford Lake Capital Management first reported a position in Viking Therapeutics in Q3 2018 and held it in 1 quarter.
  • Crawford Lake Capital Management's Viking Therapeutics position peaked at $1.92M in Q3 2018.
  • 168 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2018.

Based on Crawford Lake Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.